Pregnancy in Parkinson’s disease: case report and discussion

References

• Shulman LM, Minager A, Weiner WJ. The effect of pregnancy in Parkinson’s disease. Mov. Disord.15, 132–135 (2000).
   PubMed Web of Science ®Google Scholar
• Scott M, Chowdhury M. Pregnancy in Parkinson’s disease: unique case report and review of the literature. Mov. Disord.20, 1078–1079 (2005).
   PubMedGoogle Scholar
• Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P. Pramipexole-treated Parkinson’s disease during pregnancy. Mov. Disord.19, 1114–1115 (2004).
   PubMed Web of Science ®Google Scholar
• Golbe LI. Parkinson’s disease and pregnancy. Neurology37, 1245–1249 (1987).
   PubMedGoogle Scholar
• Routiot T, Lurel S, Denis E, Barbarino-Monnier P. Parkinson’s disease and pregnancy: case report and literature review. J. Gynecol. Obstet. Biol. Reprod. (Paris)29(5), 454–457 (2000).
   PubMedGoogle Scholar
• Kupsch A, Oertel WH. Selegiline, pregnancy, and Parkinson’s disease. Mov. Disord.13(1), 175–176 (1998).
   PubMedGoogle Scholar
• Hagell P, Odin P, Vinge E. Pregnancy in Parkinson’s disease: a review of the literature and a case report. Mov. Disord.13(1), 34–38 (1998).
   PubMed Web of Science ®Google Scholar
• Jacquemard F, Palaric JC, Allain H, Giraud JR. Parkinson disease and pregnancy. Apropos of a case. J. Gynecol. Obstet. Biol. Reprod. (Paris)19(4), 461–463 (1990).
   PubMedGoogle Scholar
• Cook DG, Klawans HL. Levodopa during pregnancy. Clin. Neuropharmacol.8, 93–95 (1985).
   PubMedGoogle Scholar
• De Mari M, Zenzola A, Lamberti P. Antiparkinsonian treatment in pregnancy. Mov. Disord.17(2), 428–429 (2002).
   PubMedGoogle Scholar
• Lindh J. Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine. Mov. Disord.22(10), 1515–1519 (2007).
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Parker WD, Currie LJ et al. Gender ratio differences between Parkinson’s disease patients and their affected relatives. Parkinsonism Relat. Disord.7(2), 129–133 (2001).
   PubMedGoogle Scholar
• Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology52(6), 1214–1220 (1999).
   PubMed Web of Science ®Google Scholar
• Van Den Eeden SK, Tanner CM, Bernstein AL et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol.157(11), 1015–1022 (2003).
   PubMed Web of Science ®Google Scholar
• NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology66(5), 664–671 (2006).
   PubMed Web of Science ®Google Scholar
• NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology68(1), 20–28 (2007).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch. Neurol.58, 1611–1615 (2001).
   PubMedGoogle Scholar
• Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med.328, 176–183 (1993).
   PubMed Web of Science ®Google Scholar
• Rajput MI, Rajput A, Rajput AH. Gender differences at Parkinson’s disease presentation in a movement disorders clinic. Mov. Disord.19(9), 1118–1134 (2004).
   Google Scholar
• Scott B, Borgman A, Engler H, Johnels B, Aquilonius SM. Gender differences in Parkinson’s disease symptom profile. Acta Neurol. Scand.102(1), 37–43 (2000).
   PubMed Web of Science ®Google Scholar
• Malecki EA, Vaughan CG, Anderson KE et al. What symptoms are most troubling to patients with Parkinson’s disease. Neurology62(Suppl. 5), A50 (2004).
   Google Scholar
• Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann. Neurol.39, 37–45(1996).
   PubMed Web of Science ®Google Scholar
• Zappia M, Annesi G, Nicoletti G et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch. Neurol.62, 601–605 (2005).
   PubMed Web of Science ®Google Scholar
• Zappia M, Crescibene L, Arabia G et al. Body weight influences pharmacokinetics of levodopa in Parkinson’s disease. Clin. Neuropharmacol.25(2), 79–82 (2002).
   PubMed Web of Science ®Google Scholar
• Growden JH, Kieburtz K, McDermott MP et al. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson’s disease patients. Neurology50, 1227–1231 (1998).
   Google Scholar
• Martenelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences. Neurol. Sci.24(3), 192–193 (2003).
   PubMedGoogle Scholar
• Kompoliti K. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology58, 1412–1422 (2002).
   PubMed Web of Science ®Google Scholar
• Wright CE, Sisson TL, Ichpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J. Clin. Pharmacol.37(6), 520–525 (1997).
   PubMed Web of Science ®Google Scholar
• Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin. Pharmacokinet.39(4), 243–254 (2000).
   PubMed Web of Science ®Google Scholar
• Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology50(Suppl. 5), S31–S38 (1998).
   Google Scholar
• Parashos SA. Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. Clin. Neuropharmacol.27(3), 119–123 (2004).
   PubMed Web of Science ®Google Scholar
• Thulin P, Carter JH, Nichols MD, Kurth M, Nutt JG. Menstrual-cycle related changes in Parkinson’s disease. Neurology46, A376 (1996).
   Google Scholar
• Horstink MW, Strijkse E, Dulzen DE. Estrogen and Parkinson’s disease. Adv. Neurol.91, 107–114 (2003).
   PubMedGoogle Scholar
• Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson’s disease. Mov. Disord.1, 85–87 (1986).
   PubMedGoogle Scholar
• Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with Parkinson’s disease. Neurology55(10), 1572–1575 (2000).
   PubMed Web of Science ®Google Scholar
• Ragonese P, D’Amelio M, Salemi G et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology62, 2010–2014 (2004).
   PubMed Web of Science ®Google Scholar
• Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J. Neurochem.65(4), 1651–1657 (1995).
   PubMedGoogle Scholar
• Xiao L, Becker JB. Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release. Synapse29(4), 379–391 (1998).
   PubMedGoogle Scholar
• Disshon KA, Boja JW, Dluzen DE. Inhibition of striatal dopamine transporter activity by 17 β-estradiol. Eur. J. Pharmacol.345(2), 207–211 (1998).
   PubMed Web of Science ®Google Scholar
• Bazzett TJ, Becker JB. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. Brain Res.637, 163–172 (1994).
   PubMed Web of Science ®Google Scholar
• Kuppers E, Ivanova T, Karolezak M, Beyer C. Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons. J. Neurocytol.29, 375–385 (2000).
   PubMedGoogle Scholar
• Kita T, Wagner GC, Nakashima TJ. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. Pharmacol. Sci.92(3), 178–195 (2003).
   Google Scholar
• Langston JW, Langston EB, Irwin I. MPTP-induced parkinsonism in human and non-human primates – clinical and experimental aspects. Acta Neurol. Scand. Suppl.100, 49–54 (1984).
   PubMedGoogle Scholar
• Gao X, Dluzen DE. Tamoxifen abolishes estrogen’s neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience103(2), 385–394 (2001).
   PubMed Web of Science ®Google Scholar
• Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson’s disease and memory. J Neurosci.20, 8604–8609 (2000).
   PubMed Web of Science ®Google Scholar
• Behl C, Skutella T, Lezoualch F et al. Neuroprotection against oxidative stress by estrogens: structure–activity relationship. Mol. Pharmacol.51, 535–541 (1997).
   PubMed Web of Science ®Google Scholar
• Woolley CS. Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Horm. Behav.34, 140–148 (1998).
   PubMed Web of Science ®Google Scholar
• Kenchappa RS, Reandrancth V. Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP. FASEB J.17(6), 717–719 (2003).
   PubMedGoogle Scholar
• Kenchappa RS, Diawaker L, Annepu J, Ravindranath V. Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J.18, 1102–1104 (2004).
   PubMed Web of Science ®Google Scholar
• Merchant CA, Cohen G, Mytilineous C et al. Human transplacental transmission of carbidopa/levodopa. Neurology44(Suppl. 2), A247–A248 (1994).
   Google Scholar
• Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA247, 1589–1591 (1982).
   PubMed Web of Science ®Google Scholar